 |
PDBsum entry 1rkp
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structure of pde5a1-ibmx
|
|
Structure:
|
 |
Cgmp-specific 3',5'-cyclic phosphodiesterase. Chain: a. Fragment: catalytic domain (residues 535-860). Synonym: cgb-pde, cgmp-binding cgmp-specific phosphodiesterase. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: pde5a, pde5, pde5a1. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Resolution:
|
 |
|
2.05Å
|
R-factor:
|
0.220
|
R-free:
|
0.243
|
|
|
Authors:
|
 |
Q.Huai,Y.Liu,S.H.Francis,J.D.Corbin,H.Ke
|
Key ref:
|
 |
Q.Huai
et al.
(2004).
Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity.
J Biol Chem,
279,
13095-13101.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
22-Nov-03
|
Release date:
|
30-Mar-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
O76074
(PDE5A_HUMAN) -
cGMP-specific 3',5'-cyclic phosphodiesterase from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
875 a.a.
311 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 1 residue position (black
cross)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.1.4.35
- 3',5'-cyclic-GMP phosphodiesterase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
3',5'-cyclic GMP + H2O = GMP + H+
|
 |
 |
 |
 |
 |
3',5'-cyclic GMP
Bound ligand (Het Group name = )
matches with 50.00% similarity
|
+
|
H2O
|
=
|
GMP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Biol Chem
279:13095-13101
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity.
|
|
Q.Huai,
Y.Liu,
S.H.Francis,
J.D.Corbin,
H.Ke.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Cyclic nucleotide phosphodiesterases (PDEs) are a superfamily of enzymes
controlling cellular concentrations of the second messengers cAMP and cGMP.
Crystal structures of the catalytic domains of cGMP-specific PDE5A1 and
cAMP-specific PDE4D2 in complex with the nonselective inhibitor
3-isobutyl-1-methylxanthine have been determined at medium resolution. The
catalytic domain of PDE5A1 has the same topological folding as that of PDE4D2,
but three regions show different tertiary structures, including residues 79-113,
208-224 (H-loop), and 341-364 (M-loop) in PDE4D2 or 535-566, 661-676, and
787-812 in PDE5A1, respectively. Because H- and M-loops are involved in binding
of the selective inhibitors, the different conformations of the loops, thus the
distinct shapes of the active sites, will be a determinant of inhibitor
selectivity in PDEs. IBMX binds to a subpocket that comprises key residues
Ile-336, Phe-340, Gln-369, and Phe-372 of PDE4D2 or Val-782, Phe-786, Gln-817,
and Phe-820 of PDE5A1. This subpocket may be a common site for binding
nonselective inhibitors of PDEs.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
FIG. 1. Structures of the PDE-IBMX complexes. A, ribbon
diagram of PDE4D2-IBMX. The -helices are colored as
cyan, and blue color represents 3[10] helices. The first metal
ion is interpreted as zinc, as discussed previously (31, 33),
whereas the second metal ion (Me2) is ambiguous. B, ribbon
diagram of PDE5A1-IBMX. The second metal ion was assigned as
magnesium because 0.2 M MgSO[4] was used in the crystallization
buffer. C, the structural superposition between PDE4D2 and
PDE5A1. The cyan ribbons represent the conserved core structures
between PDE4D2 and PDE5A1. The variable regions are drawn in
gold for PDE4D2 and green for PDE5A1. D, the correspondence of
amino acid sequence to the secondary structures.
|
 |
Figure 2.
FIG. 2. IBMX binding. Stereoview of the electron density
for IBMX bound to PDE4D2 (A) and PDE5A1 (B). The 2F[o] - F[c]
maps were calculated from the structures omitted IBMX and
contoured at 1.5 for PDE4D2 and 2.0 for
PDE5A1. C, chemical structure of IBMX. D, IBMX binding to the
active site of PDE4D2. The xanthine group stacks against Phe-372
and forms hydrogen bond with Gln-369 (dotted lines). E, IBMX
binding to the active site of PDE5A1.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2004,
279,
13095-13101)
copyright 2004.
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
R.Raijmakers,
P.Dadvar,
S.Pelletier,
J.Gouw,
K.Rumpel,
and
A.J.Heck
(2010).
Target profiling of a small library of phosphodiesterase 5 (PDE5) inhibitors using chemical proteomics.
|
| |
ChemMedChem,
5,
1927-1936.
|
 |
|
|
|
|
 |
Y.Zhang,
E.L.Pohlmann,
J.Serate,
M.C.Conrad,
and
G.P.Roberts
(2010).
Mutagenesis and functional characterization of the four domains of GlnD, a bifunctional nitrogen sensor protein.
|
| |
J Bacteriol,
192,
2711-2721.
|
 |
|
|
|
|
 |
Z.Zhang,
and
N.O.Artemyev
(2010).
Determinants for phosphodiesterase 6 inhibition by its gamma-subunit.
|
| |
Biochemistry,
49,
3862-3867.
|
 |
|
|
|
|
 |
A.P.Skoumbourdis,
C.A.Leclair,
E.Stefan,
A.G.Turjanski,
W.Maguire,
S.A.Titus,
R.Huang,
D.S.Auld,
J.Inglese,
C.P.Austin,
S.W.Michnick,
M.Xia,
and
C.J.Thomas
(2009).
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
|
| |
Bioorg Med Chem Lett,
19,
3686-3692.
|
 |
|
|
|
|
 |
B.Barren,
L.Gakhar,
H.Muradov,
K.K.Boyd,
S.Ramaswamy,
and
N.O.Artemyev
(2009).
Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the gamma-subunit.
|
| |
EMBO J,
28,
3613-3622.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.L.Weeks,
J.D.Corbin,
and
S.H.Francis
(2009).
Interactions between cyclic nucleotide phosphodiesterase 11 catalytic site and substrates or tadalafil and role of a critical Gln-869 hydrogen bond.
|
| |
J Pharmacol Exp Ther,
331,
133-141.
|
 |
|
|
|
|
 |
J.Pandit,
M.D.Forman,
K.F.Fennell,
K.S.Dillman,
and
F.S.Menniti
(2009).
Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct.
|
| |
Proc Natl Acad Sci U S A,
106,
18225-18230.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
G.Chen,
H.Wang,
H.Robinson,
J.Cai,
Y.Wan,
and
H.Ke
(2008).
An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies.
|
| |
Biochem Pharmacol,
75,
1717-1728.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.Wang,
M.Ye,
H.Robinson,
S.H.Francis,
and
H.Ke
(2008).
Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.
|
| |
Mol Pharmacol,
73,
104-110.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.Wang,
Z.Yan,
S.Yang,
J.Cai,
H.Robinson,
and
H.Ke
(2008).
Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity.
|
| |
Biochemistry,
47,
12760-12768.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Liu,
M.N.Mansour,
K.S.Dillman,
J.R.Perez,
D.E.Danley,
P.A.Aeed,
S.P.Simons,
P.K.Lemotte,
and
F.S.Menniti
(2008).
Structural basis for the catalytic mechanism of human phosphodiesterase 9.
|
| |
Proc Natl Acad Sci U S A,
105,
13309-13314.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Zheng,
G.Kaur,
H.Wang,
M.Li,
M.Macnaughtan,
X.Yang,
S.Reid,
J.Prestegard,
B.Wang,
and
H.Ke
(2008).
Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.
|
| |
J Med Chem,
51,
7673-7688.
|
 |
|
|
|
|
 |
X.J.Zhang,
K.B.Cahill,
A.Elfenbein,
V.Y.Arshavsky,
and
R.H.Cote
(2008).
Direct allosteric regulation between the GAF domain and catalytic domain of photoreceptor phosphodiesterase PDE6.
|
| |
J Biol Chem,
283,
29699-29705.
|
 |
|
|
|
|
 |
Y.Xiong,
H.T.Lu,
and
C.G.Zhan
(2008).
Dynamic structures of phosphodiesterase-5 active site by combined molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.
|
| |
J Comput Chem,
29,
1259-1267.
|
 |
|
|
|
|
 |
H.Wang,
Y.Liu,
J.Hou,
M.Zheng,
H.Robinson,
and
H.Ke
(2007).
Structural insight into substrate specificity of phosphodiesterase 10.
|
| |
Proc Natl Acad Sci U S A,
104,
5782-5787.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
H.Wang,
Z.Yan,
J.Geng,
S.Kunz,
T.Seebeck,
and
H.Ke
(2007).
Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors.
|
| |
Mol Microbiol,
66,
1029-1038.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Conti,
and
J.Beavo
(2007).
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.
|
| |
Annu Rev Biochem,
76,
481-511.
|
 |
|
|
|
|
 |
N.Kondo,
N.Nakagawa,
A.Ebihara,
L.Chen,
Z.J.Liu,
B.C.Wang,
S.Yokoyama,
S.Kuramitsu,
and
R.Masui
(2007).
Structure of dNTP-inducible dNTP triphosphohydrolase: insight into broad specificity for dNTPs and triphosphohydrolase-type hydrolysis.
|
| |
Acta Crystallogr D Biol Crystallogr,
63,
230-239.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
V.Oganesyan,
P.D.Adams,
J.Jancarik,
R.Kim,
and
S.H.Kim
(2007).
Structure of O67745_AQUAE, a hypothetical protein from Aquifex aeolicus.
|
| |
Acta Crystallogr Sect F Struct Biol Cryst Commun,
63,
369-374.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.Lugnier
(2006).
Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.
|
| |
Pharmacol Ther,
109,
366-398.
|
 |
|
|
|
|
 |
D.Wang,
and
X.Cui
(2006).
Evaluation of PDE4 inhibition for COPD.
|
| |
Int J Chron Obstruct Pulmon Dis,
1,
373-379.
|
 |
|
|
|
|
 |
H.A.Ghofrani,
I.H.Osterloh,
and
F.Grimminger
(2006).
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.
|
| |
Nat Rev Drug Discov,
5,
689-702.
|
 |
|
|
|
|
 |
H.Suzuki,
H.Sawanishi,
M.Nomura,
T.Shimada,
and
K.Miyamoto
(2006).
Effects of 1-benzylxanthines on cyclic AMP phosphodiesterase 4 isoenzyme.
|
| |
Biol Pharm Bull,
29,
131-134.
|
 |
|
|
|
|
 |
K.S.Kim,
J.A.Kim,
S.Y.Eom,
S.H.Lee,
K.R.Min,
and
Y.Kim
(2006).
Inhibitory effect of piperlonguminine on melanin production in melanoma B16 cell line by downregulation of tyrosinase expression.
|
| |
Pigment Cell Res,
19,
90-98.
|
 |
|
|
|
|
 |
Q.Huai,
Y.Sun,
H.Wang,
D.Macdonald,
R.Aspiotis,
H.Robinson,
Z.Huang,
and
H.Ke
(2006).
Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.
|
| |
J Med Chem,
49,
1867-1873.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.Xiong,
H.T.Lu,
Y.Li,
G.F.Yang,
and
C.G.Zhan
(2006).
Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.
|
| |
Biophys J,
91,
1858-1867.
|
 |
|
|
|
|
 |
Z.Zhou,
X.Wang,
H.Y.Liu,
X.Zou,
M.Li,
and
T.C.Hwang
(2006).
The two ATP binding sites of cystic fibrosis transmembrane conductance regulator (CFTR) play distinct roles in gating kinetics and energetics.
|
| |
J Gen Physiol,
128,
413-422.
|
 |
|
|
|
|
 |
A.Castro,
M.J.Jerez,
C.Gil,
and
A.Martinez
(2005).
Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
|
| |
Med Res Rev,
25,
229-244.
|
 |
|
|
|
|
 |
F.V.Rao,
O.A.Andersen,
K.A.Vora,
J.A.Demartino,
and
D.M.van Aalten
(2005).
Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes.
|
| |
Chem Biol,
12,
973-980.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.Y.Zhang,
P.N.Ibrahim,
S.Gillette,
and
G.Bollag
(2005).
Phosphodiesterase-4 as a potential drug target.
|
| |
Expert Opin Ther Targets,
9,
1283-1305.
|
 |
|
|
|
|
 |
M.D.Houslay,
P.Schafer,
and
K.Y.Zhang
(2005).
Keynote review: phosphodiesterase-4 as a therapeutic target.
|
| |
Drug Discov Today,
10,
1503-1519.
|
 |
|
|
|
|
 |
X.Zhang,
Q.Feng,
and
R.H.Cote
(2005).
Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors.
|
| |
Invest Ophthalmol Vis Sci,
46,
3060-3066.
|
 |
|
|
|
|
 |
Z.Zhou,
X.Wang,
M.Li,
Y.Sohma,
X.Zou,
and
T.C.Hwang
(2005).
High affinity ATP/ADP analogues as new tools for studying CFTR gating.
|
| |
J Physiol,
569,
447-457.
|
 |
|
|
|
|
 |
G.L.Card,
B.P.England,
Y.Suzuki,
D.Fong,
B.Powell,
B.Lee,
C.Luu,
M.Tabrizizad,
S.Gillette,
P.N.Ibrahim,
D.R.Artis,
G.Bollag,
M.V.Milburn,
S.H.Kim,
J.Schlessinger,
and
K.Y.Zhang
(2004).
Structural basis for the activity of drugs that inhibit phosphodiesterases.
|
| |
Structure,
12,
2233-2247.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.Y.Zhang,
G.L.Card,
Y.Suzuki,
D.R.Artis,
D.Fong,
S.Gillette,
D.Hsieh,
J.Neiman,
B.L.West,
C.Zhang,
M.V.Milburn,
S.H.Kim,
J.Schlessinger,
and
G.Bollag
(2004).
A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases.
|
| |
Mol Cell,
15,
279-286.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |